News | Radiopharmaceuticals and Tracers | May 22, 2017

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18

Companies also announce the extension and expansion of their existing commercial supply agreement for nuclear products through 2020

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18

May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a definitive license agreement  for the continued Phase III development and worldwide commercialization of flurpiridaz F-18. Flurpiridaz F-18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease (CAD), the most common form of heart disease. The definitive agreement follows the signing of a term sheet previously announced in late February 2017.

Under the definitive agreement, GE Healthcare will lead and fund the development program of flurpiridaz F-18, including the second Phase III clinical study. GE Healthcare will also have exclusive worldwide rights for the commercialization of flurpiridaz F-18. Lantheus will collaborate in both the development and commercialization process through a joint steering committee. Lantheus also maintains the option to co-promote the imaging agent in the United States.

Lantheus will receive a $5 million upfront cash payment and, if successful, up to $60 million in regulatory and sales milestones payments, plus double-digit royalties on U.S. sales and single-digit royalties on sales outside of the U.S.

Separately, the companies have also extended and expanded their current commercial agreement under which Lantheus will continue to supply GE Healthcare with TechneLite (Technetium Tc99m Generators), Gallium-67 (Gallium Citrate Ga 67 Injection) and Xenon-133 (Xenon Xe 133 Gas) through Dec. 31, 2020.

For more information: www.gehealthcare.com, www.lantheus.com

Related Content

News | Cardiac Imaging

November 10, 2021 — Philips, a global leader in health technology, announced that it has signed an agreement to acquire ...

Home November 10, 2021
Home
News | Cardiac Imaging

November 1, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), radiologists need to be cognizant of the ...

Home November 01, 2021
Home
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Home October 06, 2021
Home
News | Cardiac Imaging

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by ...

Home September 22, 2021
Home
Feature | Cardiac Imaging | By Dave Fornell, Editor

In the past several years, a few cardiac ultrasound vendors have developed new ways to image the intricate flow of ...

Home August 17, 2021
Home
News | Cardiac Imaging

June 15, 2021 — A cardiac MRI of athletes who had COVID-19 is seven times more effective in detecting inflammation of ...

Home June 15, 2021
Home
News | Cardiac Imaging

June 14, 2021 — Heart disease and cancer are the leading causes of death in the United States, and it’s increasingly ...

Home June 14, 2021
Home
News | Cardiac Imaging

May 12, 2021 — According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 ...

Home May 12, 2021
Home
News | Cardiac Imaging

March 31, 2021 — ScImage Inc. celebrates its cloud partnership with Digirad Health after a year of successful deployment ...

Home March 31, 2021
Home
Subscribe Now